Scilex Holding Company: updates and filings

SCLXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.59

November 17, 2026Market cap $5.0M

What Ploutos Investor adds for Scilex

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 82% since Aug 14, 2026, when the 10-Q these figures come from was filed ($6.76 then, $1.25 on Nov 16, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

4 days agoAround Nov 13, 2026 · for Q3 2026

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Apr 10, 2026 latest annualAug 14, 2026 latest quarterly
  • Sep 29, 2026Material agreement entered
    Form8-K
  • Aug 24, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 12, 2026Material agreement entered
    Form8-K
  • Jul 22, 2026Material agreement entered, acquisition or disposal of assets
    Form8-K
  • Jul 7, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 6, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Jun 30, 2026Shares registered for employees
    FormS-8
  • Jun 29, 2026Material agreement entered, unregistered sale of shares
    Form8-K
  • Jun 26, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jun 24, 2026Shareholder vote
    Form8-K
  • Jun 11, 2026Filing
    FormEFFECT
  • Jun 9, 2026Correspondence with the SEC
    FormCORRESP
  • Jun 9, 2026Letter from the SEC
    FormUPLOAD
  • Jun 2, 2026Shelf registration for future offerings
    FormS-3
  • May 22, 2026Filing
    FormEFFECT
  • May 20, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 20, 2026Correspondence with the SEC
    FormCORRESP
  • May 15, 2026Notice that the quarterly report will be filed late
    FormNT 10-Q
  • May 11, 2026Other material events
    Form8-K
  • May 5, 2026Additional annual meeting material
    FormDEFA14A
  • May 5, 2026Material agreement entered, Regulation FD disclosure
    Form8-K
  • Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 30, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 30, 2026Correspondence with the SEC
    FormCORRESP

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 19, 2020. Of its note and share prospectuses (424B, FWP), the newest 40 of 255.

The full analysis

What do Scilex's filings show?

The filings are where every one of Scilex's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.